Phase 3Active, not recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes (KaiNETIC-1)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Sponsor
- Kailera (Industry)
- Enrolment
- 2,530 enrolled
- Conditions
- Obesity; Overweight
- Interventions
- Ribupatide; Placebo
- Ages
- adults, older adults
- Registry
- NCT07284875
Full record on ClinicalTrials.gov
From the registry
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Primary outcomes
- Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered